A Study of Galcanezumab in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purposes of this study are: * To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A) * To measure how much of the Galcanezumab lyophilized (freeze dried) injectable formulation is absorbed into the blood stream and how long it takes the body to get rid of it compared to the Galcanezumab solution injectable formulation after a single injection under the skin (subcutaneous \[SC\]) (Part B). Information about any side effects that may occur will also be collected. Each part of the study will last about six months. Participants may only enroll in one part.

Key facts

Study ID

NCT02576951

Run by

Eli Lilly and Company

People needed

178

Starts

2015-10-19

Expected to finish

2018-01-08

Last updated by the study team

2019-02-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female healthy participants
• Have a body mass index of 19.0 to 35.0 kilograms per meter square (kg/m²), inclusive

You may not qualify if…

• Currently smoke in excess of 5 cigarettes/day

Where it is running

• Covance — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.